Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

An Epidemic of EpiPens

By University of Birmingham | March 21, 2017

Researchers at the University of Birmingham have found that prescriptions of adrenaline autoinjectors (commonly called ‘epipens’) for children with allergies have increased markedly in the last decade, with nearly four devices a year provided per child.

The researchers looked at a database of patient records from over 500 general practices, THIN (the Health Improvement Network), between 2000 and 2012. They found nearly 24,000 children who had been identified as being at risk of anaphylaxis by General Practitioners and prescribed epipens.

Over the 12 year period the number of children identified by GPs as being at risk increased three and a half times, and the total number of devices prescribed (per 1000 person years) in the UK increased five-fold.

The research, published in British Journal of General Practice, notes that there has been little guidance for GPs on the optimal use of epipens – but the most recent guidelines suggest that each child should be given no more than two devices.

The team hope that the findings will prompt an informed discussion on the management of children with serious allergies, specifically how many devices should be prescribed per child. The goal would be to reduce unnecessary prescriptions without compromising child safety.

As the devices require annual renewal, and as per the estimates in the study, the cost to the tax payer could be as much as £7 million per year (for children under the age of 17).

Dr Lavanya Diwakar, from the University of Birmingham, explained, ‘Of course, adrenaline autoinjectors are life-saving for those at a high risk of anaphylaxis- but current prescribing trends would appear to be wasteful.

‘It may be that GPs are taking a cautious approach, or that parents are requesting extra devices to cover all of the areas that their child might go, and both are completely understandable. In the absence of clear guidelines, that’s a natural tendency. However, there is no evidence that prescribing multiple devices improves safety. What is more important is to ensure that these children carry their device with them at all times and can use them correctly in the event of an emergency.

‘Now we’re seeing the extent of this trend, it’s time to have a constructive discussion about how we manage serious allergies in a more efficient manner.’

Related Articles Read More >

5 R&D developments to keep an eye on this week: Solar crash and Trump’s energy pivot meets Musk’s rebellion
Mayo Clinic develops AI tool that can spot 9 dementia types with a single scan
Google DeepMind’s AlphaGenome AI predicts how non-coding DNA can drive disease
Top 10 drugs by patent volume: How biologics build ‘platform empires’ while small molecule create ‘patent thickets’
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE